JPMorgan Starts ConforMIS (CFMS) at Overweight

Go back to JPMorgan Starts ConforMIS (CFMS) at Overweight

UPDATE: Oppenheimer Starts ConforMIS (CFMS) at Outperform

July 27, 2015 7:40 AM UTC

(Updated - July 27, 2015 9:12 AM EDT)

Oppenheimer initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating and a price target of $26.

Analyst Steven Lichtman said, "CFMS's unique iFit technology provides custom implants designed to match the individual anatomy of a patient undergoing total... More

Wells Fargo Starts ConforMIS (CFMS) at Outperform

July 27, 2015 7:38 AM UTC

Wells Fargo initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating.

For an analyst ratings summary and ratings history on ConforMIS click here. For more ratings news on ConforMIS click here.

Shares of ConforMIS closed at $22.12 yesterday.

... More

UPDATE: Canaccord Genuity Starts ConforMIS (CFMS) at Buy

July 27, 2015 7:37 AM UTC

(Updated - July 27, 2015 8:47 AM EDT)

Canaccord Genuity initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.00.

Analyst William J. Plovanic said, "We believe ConforMIS is a disruptive technology in the multi-billion dollar global orthopedic implant market.... More

Deutsche Bank Starts ConforMIS (CFMS) at Buy

July 27, 2015 7:36 AM UTC

Deutsche Bank initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.

Analyst Kristen Stewart said, "ConforMIS is an orthopedic manufacturer of fully customized implants utilizing its iFit technology--iFit design, iFit printing (3D printing), and iFit just-in-time... More